Daxor Corporation
DXR
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $60.0M
$10.27
▼ -2.66%
P/E
-15.56
Mkt Cap
$60.0M
52-Wk Range
$8.56–$14.76
52-Week Range
$8.56 - $14.76
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 10.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
+1.7% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying DXR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 31, 2026
Reported EPS of -$0.66 vs -$0.06 consensus (-1000.0% surprise). Revenue of $23.0K vs $2.8M expected (-99.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1000.0%
Revenue trend · last 1Q
+25%
Q2 26
$23.0K
Margins · last 1Q
Profit
-14382.9%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How DXR stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.